Logo image of PROG

BIORA THERAPEUTICS INC (PROG) Stock Fundamental Analysis

NASDAQ:PROG - Nasdaq - US74319F1075 - Common Stock

0.8845  -0.03 (-3.47%)

After market: 0.9 +0.02 (+1.75%)

Fundamental Rating

1

PROG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PROG have multiple concerns. PROG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PROG has reported negative net income.
PROG Yearly Net Income VS EBIT VS OCF VS FCFPROG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -227.32%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROG Yearly ROA, ROE, ROICPROG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 -2K -4K -6K

1.3 Margins

Industry RankSector Rank
OM -517.86%
PM (TTM) -966.06%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROG Yearly Profit, Operating, Gross MarginsPROG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -5K -10K -15K

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, PROG has more shares outstanding
Compared to 1 year ago, PROG has a worse debt to assets ratio.
PROG Yearly Shares OutstandingPROG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 50M 100M 150M
PROG Yearly Total Debt VS Total AssetsPROG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

PROG has an Altman-Z score of -12.84. This is a bad value and indicates that PROG is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -1.49 indicates that PROG is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Altman-Z -12.84
ROIC/WACCN/A
WACCN/A
PROG Yearly LT Debt VS Equity VS FCFPROG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.60 indicates that PROG should not have too much problems paying its short term obligations.
A Quick Ratio of 1.60 indicates that PROG should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
PROG Yearly Current Assets VS Current LiabilitesPROG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.83% over the past year.
The Revenue for PROG has decreased by -65.54% in the past year. This is quite bad
The Revenue for PROG have been decreasing by -78.64% on average. This is quite bad
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%

3.2 Future

The Earnings Per Share is expected to grow by 12.23% on average over the next years. This is quite good.
Based on estimates for the next years, PROG will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PROG Yearly Revenue VS EstimatesPROG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 50M 100M
PROG Yearly EPS VS EstimatesPROG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PROG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROG Price Earnings VS Forward Price EarningsPROG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.53
PROG Per share dataPROG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PROG's earnings are expected to grow with 20.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.26%
EPS Next 3Y20.89%

More info and screens

0

5. Dividend

5.1 Amount

PROG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORA THERAPEUTICS INC

NASDAQ:PROG (5/6/2022, 8:00:02 PM)

After market: 0.9 +0.02 (+1.75%)

0.8845

-0.03 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-10 2022-05-10/amc
Earnings (Next)08-10 2022-08-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.45%
Ins Owner Change0%
Market Cap162.92M
Analysts82.86
Price Target4.08 (361.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -1.53
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.14
BVpS-0.46
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -227.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -517.86%
PM (TTM) -966.06%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -12.84
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A